Evidence map›Paper›PMID 37908370›Full record

ArticleNigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria

COVID-19 Subclinical Infection and Immunity: A Review.

Joyce Weade Bartekwa, Esala Ezekiel Abene, Pam Dachung Luka, Christopher Sabo Yilgwan, Nathan Yakubu Shehu

Open access · goldAbstract read
In one paragraph

Article in Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Joyce Weade BartekwaDepartment of Medicine, Jos University Teaching Hospital, Jos.
Esala Ezekiel AbeneDepartment of Medicine, Jos University Teaching Hospital, Jos.
Pam Dachung LukaNational Veterinary Research Institute Vom, Plateau State, Nigeria.
Christopher Sabo YilgwanDepartment of Paediatrics, University of Jos/Jos University Teaching Hospital, Jos.
Nathan Yakubu ShehuDepartment of Medicine, Jos University Teaching Hospital, Jos.
Jos University Teaching Hospital · NGNational Veterinary Research Institute · NGUniversity of Jos · NG

Funding

West African Center for Emerging Infectious DiseasesU01AI151801 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Robert W Cross, Scott C Weaver · 2020 to 2026
$10.1M
Sequelae of Lassa FeverR01AI129198 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI PAESSLER, SLOBODAN · 2018 to 2022
$3.9M
Training and Research on Arboviruses and Zoonoses In Nigeria and Sierra Leone (TRAIN)D43TW012246 · FIC · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Nikos Vasilakis, Scott C Weaver · 2022 to 2026
$1.2M
FIC NIH HHS D43 TW012246NIAID NIH HHS R01 AI129198NIAID NIH HHS U01 AI151801
6 · The paper itself

Abstract

The aetiologic agent of COVID-19 is a novel coronavirus, SARS-CoV-2. Like other coronaviruses, it generally induces enteric and respiratory diseases in animals and humans. COVID-19 may be subclinical, and symptomatic, ranging from mild-to-severe disease. The spectrum of presentation is the result of several factors ranging from the inoculum size, inherent host susceptibility, possible cross-reacting circulating antibodies. Subclinical viral infections are associated with widespread community transmission and in some cases like Polio, herd immunity. An understanding of the biology and immune behavior in subclinical coronavirus disease 2019 (COVID-19) might be useful in the quest for vaccine development as well as the current control efforts against the COVID-19 pandemic. We carried out a narrative review of the available literature on the biology, etiopathogenesis, clinical manifestation of SARS-CoV-2 viral infection, focusing on our current understanding of the disease mechanisms and its clinical manifestation, and the host immune response to the infection. We also highlighted some of the research gaps regarding subclinical infection in COVID-19 and its potential application for vaccine development and other preventive efforts toward containing the current COVID-19 pandemic.

Indexed as

coronavirus disease 2019CoronavirusesimmunitySARS-CoV-2subclinical infection

Identifiers

PMID37908370
PMCPMC10617632
OpenAlexW4206296970

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.